Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab.
BMJ Case Rep
; 17(9)2024 Sep 19.
Article
in En
| MEDLINE
| ID: mdl-39304216
ABSTRACT
This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to John Cunningham polyomavirus (JCV) reactivation.Treated with pembrolizumab, an immune checkpoint inhibitor, the patient initially improved. However, after the fourth dose, her condition rapidly worsened resulting in treatment discontinuation and death. Similar cases highlight the complex interplay of factors in PML development in SLE patients, including immunosuppression and genetic factors. The use of pembrolizumab in PML and SLE necessitates careful consideration of potential complications.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukoencephalopathy, Progressive Multifocal
/
Antibodies, Monoclonal, Humanized
/
Lupus Erythematosus, Systemic
Limits:
Female
/
Humans
Language:
En
Journal:
BMJ Case Rep
Year:
2024
Document type:
Article
Affiliation country:
Denmark
Country of publication:
United kingdom